# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects

> **NCT05045534** · PHASE1 · COMPLETED · sponsor: **Therasid Bioscience** · enrollment: 96 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Comparison of TB-840 treatment with Placebo

## Key facts

- **NCT ID:** NCT05045534
- **Lead sponsor:** Therasid Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-14
- **Primary completion:** 2022-08-29
- **Final completion:** 2022-12-30
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05045534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05045534, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05045534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*